MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

Kodu・Aktsiate loetelu・Cytek Biosciences Inc

Cytek Biosciences Inc

Suletud

SektorTervishoid

4.63 -0.86

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.45

Max

4.67

Põhinäitajad
By Trading Economics
Sissetulek	-39M -44M
Müük	9.8M 62M
Kasumimarginaal	-70.929
Töötajad	702
EBITDA	4M -263K

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+34.12% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	7. mai 2026

Turustatistika
By TradingEconomics
Turukapital	20M 581M
Eelmine avamishind	5.49
Eelmine sulgemishind	4.63

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

3.7 / 3.8 Toetus ja vastupanu

Cytek Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

ADB: Higher Energy Prices to Raise Production, Consumer Costs

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

ADB Projects Japan GDP Growth at 0.7% in 2026, 0.6% in 2027

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

ADB Projects South Korea GDP Growth at 1.9% in 2026, 1.9% in 2027

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

Extent of Slowdown Hinges on Duration of MidEast Conflict, ADB Says

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

ADB Projects India GDP Growth at 6.9% in 2026, 7.3% in 2027

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

ADB Projects China GDP Growth at 4.6% in 2026, 4.5% in 2027

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

ADB Pojects Australia GDP Grrowth at 2.0% in 2026, 2.9% in 2027

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

ADB Projects Taiwan GDP Growth at 7.6% in 2026, 4.0% in 2027

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

Geopolitical Risks Make Asia's Economic Outlook Highly Uncertain, ADB Says

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

Asia Regional Growth Likely to Moderate in 2026-2027, ADB Says

9. apr 2026, 23:44 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Talks -- Market Talk

9. apr 2026, 23:34 UTC

Market Talk

Gold Edges Lower Amid Lingering Inflation Concerns -- Market Talk

9. apr 2026, 23:14 UTC

Market Talk

Jefferies Upbeat on Australian Miners, But Recession a Key Risk -- Market Talk

9. apr 2026, 23:14 UTC

Market Talk

Global Equities Roundup: Market Talk

9. apr 2026, 23:07 UTC

Market Talk

Centaurus's Supply Deal with Glencore Supports Jaguar Development -- Market Talk

9. apr 2026, 22:54 UTC

Market Talk

Transurban Lacks Appeal as Higher Fuel Prices Slow Traffic -- Market Talk

9. apr 2026, 22:31 UTC

Uudisväärsed sündmused

Trump on Truth Social: 'That Is Not the Agreement We Have!'

9. apr 2026, 22:31 UTC

Uudisväärsed sündmused

Trump on Truth Social: 'Iran Is Doing a Very Poor Job, Dishonorable Some Would Say, of Allowing Oil to Go Through the Strait of Hormuz'

9. apr 2026, 20:57 UTC

Uudisväärsed sündmused

U.S. Oil Prices Are Back Near $100 After Israel Keeps Up Air Strikes on Lebanon -- Barrons.com

9. apr 2026, 20:55 UTC

Tulu

Stryker: Believes Incident Hasn't Had, and Isn't Reasonably Likely to Have, a Material Impact on 2026 Full-Year Guidance >SYK

9. apr 2026, 20:55 UTC

Tulu

Stryker: Determined Incident Had Material Impact on Operations, With Resulting Impact on Financial Results for 1Q >SYK

9. apr 2026, 20:55 UTC

Tulu

Stryker: Investigation of Cybersecurity Incident Remains Ongoing >SYK

9. apr 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

9. apr 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. apr 2026, 20:40 UTC

Omandamised, ülevõtmised, äriostud

Blackstone Investment Positions Rowan to Continue Delivering Sustainable Data Center Capacity for World's Leading Technology Cos >BX

9. apr 2026, 20:39 UTC

Omandamised, ülevõtmised, äriostud

Blackstone Blackstone Acquired Significant Minority Stake in Rowan Digital Infrastructure >BX

9. apr 2026, 20:39 UTC

Omandamised, ülevõtmised, äriostud

Rowan Digital Infrastructure Announces Strategic Recapitalization

9. apr 2026, 20:25 UTC

Omandamised, ülevõtmised, äriostud

SBA Communications Stock Soars on Buyout Interest. What It Means for Tower Stocks. -- Barrons.com

9. apr 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9. apr 2026, 19:30 UTC

Uudisväärsed sündmused

How Digital Currencies Have Helped Iran -- WSJ

Võrdlus sarnastega

Hinnamuutus

Cytek Biosciences Inc Prognoos

Hinnasiht

By TipRanks

34.12% tõus

12 kuu keskmine prognoos

Keskmine 6.25 USD 34.12%

Kõrge 7.5 USD

Madal 5 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Cytek Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

Osta

Hoia

Müü

Põhineb 2 analüütiku instrumendi Cytek Biosciences Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

3.7 / 3.8Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bearish.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.